Anton Pekcec

Company: Boehringer Ingelheim

Job title: Head of Diabetes & Obesity Research

Seminars:

Advancing Survodutide: Exploring the Dual Agonist’s Phase III Potential in Obesity Treatment 8:30 am

Exploring the promising Phase II results of survodutide, which demonstrated up to 19% weight loss in individuals with overweight or obesity Gain insights into the design and objectives of the upcoming global Phase III studies, focusing on the efficacy and safety of survodutide in a broader population Explore the potential of survodutide’s dual glucagon/GLP-1 receptor…Read more

day: Conference Day One

Panel Discussion: Assessing the Obesity Landscape, Examining Areas of Improvement with Current Standards of Care to Define Best in Class & Future Directions 8:00 am

What is the benchmark with the current therapeutics on the market? Where are the shortfalls we can improve upon to improve the standard of care? What is the current unmet need for patients? What do patients actually want to see improved?Read more

day: Conference Day One